Improved renal recovery in patients with atypical hemolytic uremic syndrome following rapid initiation of eculizumab treatment

BACKGROUND: Eculizumab is approved for atypical hemolytic uremic syndrome (aHUS). Guidelines discuss the importance of prompt treatment. We report a post hoc analysis investigating the effect of baseline factors, including patient characteristics and time from the latest aHUS manifestation to eculiz...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:J Nephrol
Main Authors: Walle, Johan Vande, Delmas, Yahsou, Ardissino, Gianluigi, Wang, Jimmy, Kincaid, John F., Haller, Herman
Format: Artigo
Jezik:Inglês
Izdano: Springer International Publishing 2016
Teme:
Original Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5316393/
https://ncbi.nlm.nih.gov/pubmed/26995002
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40620-016-0288-3
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki